Publications

Export 1424 results:
Sort by: Author [ Title  (Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U [V] W X Y Z   [Show ALL]
V
JL, A., A. N, P. JE, K. R, and K. NA, "VWD type 2N (Normandy) in two sisters.", Haemophilia. 2015 May;21(3):e223-5. doi: 10.1111/hae.12595. Epub 2015 Feb 4. , vol. 3, issue 10, pp. 223-5, 2015.
Soliman, W., O. Gabriel, J. J. A. v.d.Dungen, and E. R. and D. C Schram, "VUV-LIF Spectroscopy of Ro-vibrationally Excited HD Molecules Produced in Hydrogen-Deuterium Plasmas", 13th Intenational Syposium on Laser-Aided Plasma Diagnostics 2007, Japan., Japan, 2007.
J.J.A. v.d. Dungen, O. Gabriel, W. Soliman, and C. S. D. R. and Engeln., "VUV-LIF spectroscopy of Ro-vibrationally excited HD molecules produced in hydrogen-deuterium plasmas", 10th EUREGIONAL WELTPP, Workshop on the Exploration of Low Temperature Plasma Physics, Kerkrade, The Netherlands, The Netherland, 2007.
El-Dakrouri, A., J. Yan, M. C. Gupta, M. Laroussi, and Y. Badr, "VUV emission from a novel DBD-based radiation source", Journal of Physics D: Applied Physics, vol. 35, no. 21, pp. L109-L114, 2002. AbstractWebsite
n/a
El‑Shahat, S., A. M. El‑Zafarany, T. A. B. O. U. E. L. SEOUD, and S. A. Ghoniem, "Vulnerability assessment of African coasts to sea level rise using GIS and remote sensing", Environment, Development and Sustainability, vol. 23, issue 2, pp. 2827-2845, 2021.
El-Zawawy, M. A., E. Losiouk, and M. Conti, "Vulnerabilities in Android WebView Objects: Still Not the End!", Computers & Security (Q1- Impact Factor 4.438), 2021.
EL-ASSALY, M. D., and others, "VRT in Traumatic Maxillo-Facial Injuries; Is it of an Added Value Compared to Axial and Reconstructed CT Images?", The Medical Journal of Cairo University, vol. 88, no. March: The Clinical Society of Cairo University, pp. 405–411, 2020. Abstract
n/a
HM, Y., K. E, K. R, A. AM, P. N, F. A, S. S, T. A, R. T, G. G, et al., "VRS2 regulates hormone-mediated inflorescence patterning in barley", Nature Genetics, 2017. ng.3717.pdf
Xiao, S., S. Wang, D. Jiang, X. Cheng, X. Zhu, F. Lin, B. Yu, H. Dong, X. Wang, M. Munir, et al., "VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks.", Transboundary and emerging diseases, 2021. Abstract

Duckling short beak and dwarfism syndrome virus (SBDSV), an emerging goose parvovirus, has caused short beak and dwarfism syndrome (SBDS) in Chinese duck flocks since 2015. Presently, there is no commercial vaccine against SBDS. In the present study, a virus-like particle (VLP)-based candidate vaccine was developed against this disease. A baculovirus expression system was used to express the SBDSV VP2 protein in Sf9 cells. Immunofluorescence assay, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were used to confirm protein expression. Furthermore, transmission electron microscopy was used to observe the formation of VLPs. VLPs were formulated into an oil-adjuvanted maternal vaccine to evaluate humoral responses in breeding ducks via latex particle agglutination inhibition assay (LPAI) and microneutralization assay. The offspring were challenged with SBDSV to test the protective efficacy. A single dose of SBDSV was able to induce the high level of LPAI antibodies in ducks, with LPAI and neutralization peak titres of 4.9 ± 1.20 log2 and 7.1 ± 1.20 log2, respectively, at 4 weeks post-vaccination (wpv). The average LPAI titre of yolk antibodies in duck eggs receiving 2 doses (first and boost doses) of the vaccine was 5.3 ± 1.09 log2 at 4 weeks post-boost. The protective efficacy of the maternal vaccine was 87.5%-100%. These results indicate that SBDSV VLPs can be a promising vaccine candidate for controlling SBDS.

Sabry, R., Voyager d'Egypte vers l'Europe et inversement. Direction, , Paris, Classiques Garnier, 2019.
Sabry, R., Voyager d'Egypte vers l'Europe et inversement. Direction, , Paris, Classiques Garnier, 2019.
Howard, J., K. I. Ataga, R. C. Brown, M. Achebe, V. Nduba, A. El-Beshlawy, H. Hassab, I. Agodoa, M. Tonda, S. Gray, et al., "Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.", The Lancet. Haematology, vol. 8, issue 5, pp. e323-e333, 2021. Abstract

BACKGROUND: For decades, patients with sickle cell disease have had only a limited number of therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin polymerisation inhibitor, was approved in the USA for the treatment of sickle cell disease in patients aged 12 years and older on the basis of HOPE trial data. To further describe the applicability of voxelotor as a treatment for this chronic illness, we report the long-term efficacy and safety of this drug at 72 weeks of treatment; the conclusion of the placebo-controlled HOPE trial.

METHODS: HOPE is an international, randomised, double-blind, placebo-controlled, phase 3 trial done at 60 clinical sites in Canada, Egypt, France, Italy, Jamaica, Kenya, Lebanon, Netherlands, Oman, Turkey, the USA, and the UK. Patients (aged 12-65 years) with confirmed sickle cell disease, a haemoglobin concentration of 5·5-10·5 g/dL at enrolment, and who had between one and ten vaso-occlusive crisis events in the previous 12 months were enrolled. Patients receiving regularly scheduled transfusion therapy, who had received a transfusion in the previous 60 days, or who had been admitted to hospital for a vaso-occlusive crisis in the previous 14 days were excluded. Patients were randomly assigned (1:1:1) to receive either once-daily oral voxelotor 1500 mg, voxelotor 900 mg, or placebo for 72 weeks. Randomisation was done centrally by use of an interactive web response system, stratified by baseline hydroxyurea use (yes vs no), age group (adolescents [12 to <18 years] vs adults [18 to 65 years]), and geographic region (North America vs Europe vs other). The primary endpoint (already reported) was the proportion of patients who achieved a haemoglobin response at week 24. In this final analysis, we report prespecified long-term efficacy assessments by intention to treat, including changes in haemoglobin concentrations from baseline to week 72, changes in the concentration of haemolysis markers (absolute and percentage reticulocytes, indirect bilirubin concentrations, and lactate dehydrogenase concentrations) from baseline to week 72, the annualised incidence of vaso-occlusive crises, and patient functioning, as assessed with the Clinical Global Impression of Change (CGI-C) scale. Safety was assessed in patients who received at least one dose of treatment (modified intention-to-treat population). This trial is registered with ClinicalTrials.gov, NCT03036813.

FINDINGS: Between Dec 5, 2016, and May 3, 2018, 449 patients were screened, of whom 274 were randomly assigned to the voxelotor 1500 mg group (n=90), the voxelotor 900 mg group (n=92), or the placebo group (n=92). At week 72, the adjusted mean change in haemoglobin concentration from baseline was 1·0 g/dL (95% CI 0·7 to -1·3) in the voxelotor 1500 mg group, 0·5 g/dL (0·3 to -0·8) in the voxelotor 900 mg group, and 0·0 g/dL (-0·3 to 0·3) in the placebo group, with a significant difference observed between the voxelotor 1500 mg group and the placebo group (p<0·0001), and between the voxelotor 900 mg group and the placebo group (p=0·014). Significant improvements in markers of haemolysis, as assessed by the difference in adjusted mean percentage change from baseline at week 72 versus placebo, were observed in the voxelotor 1500 mg group in indirect bilirubin concentrations (-26·6% [95% CI -40·2 to -12·9]) and percentage of reticulocytes (-18·6% [-33·9 to -3·3]). The proportion of patients in the voxelotor 1500 mg group who were rated as "moderately improved" or "very much improved" at week 72 with the CGI-C was significantly greater than in the placebo group (39 [74%] of 53 vs 24 [47%] of 51; p=0·0057). Serious adverse events unrelated to sickle cell disease were reported in 25 (28%) of 88 patients in the voxelotor 1500 mg group, 20 (22%) of 92 patients in the voxelotor 900 mg group, and 23 (25%) of 91 patients in the placebo group. Grade 3 or 4 adverse events were infrequent (ie, occurred in <10% of patients); anaemia occurred in five or more patients (two [2%] patients in the voxelotor 1500 mg group, seven [8%] patients in the voxelotor 900 mg group, and three [3%] patients in the placebo group). Of all 274 patients, six (2%) deaths occurred during the study (two deaths in each treatment group), all of which were judged as unrelated to treatment.

INTERPRETATION: Voxelotor 1500 mg resulted in rapid and durable improvements in haemoglobin concentrations maintained over 72 weeks and has potential to address the substantial morbidity associated with haemolytic anaemia in sickle cell disease.

FUNDING: Global Blood Therapeutics.

Mekawy Ouda, A. M., "The votive stela of the “overseer of the singers of the king” Nfr-rnpt (Egyptian Museum Cairo TR 14.6.24.17)", Le Bulletin de l'Institut français d'archéologie orientale, vol. 116, pp. 177-189, 2016.
Ettouney, S. M., and U. Form, "Votes on the Relative Importance of Climate as a Physical Planning Determinant in Egypt", Climate and human settlements: integrating climate into urban planning and building design in Africa: United Nations Environment Programme, pp. 65, 1991. Abstract
n/a
Hafez, M., M. Hilali, and M. Refai, "Vorkommen von Pilzen im Darmtrakt einiger blutsaugender Fliegen in Agypten", Wiener tierarztliche Monatsschrift, 1976. Abstract
n/a
Fahmy, A. M., M. Hassan, D. A. El-Setouhy, S. A. Tayel, and A. M. Al-mahallawi, "Voriconazole Ternary Micellar Systems for the Treatment of Ocular Mycosis: Statistical Optimization and In Vivo Evaluation.", Journal of pharmaceutical sciences, 2020. Abstract

Voriconazole (VRC) is a broad spectrum, second generation triazole antifungal. The main use of VRC is via the oral and intravenous route. The study aimed to formulate VRC into ternary micellar systems (TMSs) for the topical treatment of ocular mycosis. TMSs were successfully prepared by water addition/solvent evaporation method, applying a 3-factor D-optimal design. The numerical optimization process suggested an optimal formula (OTMS) composed of total Pluronics to drug weight ratio of 22.89: 1, 1:1 weight ratio of Pluronic® P123 and F68, and 2% w/v of Labrasol. OTMS had high solubilization efficiency of 98.0%, small micellar size of 21.8 nm and suitable zeta potential and polydispersity index values of -9.0 mV and 0.261, respectively. OTMS exhibited acceptable stability for 3 months. Transmission electron microscopy demonstrated the spherical morphology of micelles. OTMS was expected to cause no ocular irritation or blurring in vision as reflected by pH and refractive index measurements. The histopathological study revealed the safety of OTMS for ocular use. The fungal susceptibility testing using Candida albicans demonstrated the superiority of OTMS to VRC suspension, with greater and more durable growth inhibition. Therefore, ocular application of optimized VRC-loaded TMSs can be a promising treatment for ocular mycosis.

Fahmy, A. M., M. Hassan, D. A. El-Setouhy, S. A. Tayel, and A. M. Al-mahallawi, "Voriconazole Ternary Micellar Systems for the Treatment of Ocular Mycosis: Statistical Optimization and In Vivo Evaluation.", Journal of pharmaceutical sciences, vol. 110, issue 5, pp. 2130-2138, 2021. Abstract

Voriconazole (VRC) is a broad spectrum, second generation triazole antifungal. The main use of VRC is via the oral and intravenous route. The study aimed to formulate VRC into ternary micellar systems (TMSs) for the topical treatment of ocular mycosis. TMSs were successfully prepared by water addition/solvent evaporation method, applying a 3-factor D-optimal design. The numerical optimization process suggested an optimal formula (OTMS) composed of total Pluronics to drug weight ratio of 22.89: 1, 1:1 weight ratio of Pluronic® P123 and F68, and 2% w/v of Labrasol. OTMS had high solubilization efficiency of 98.0%, small micellar size of 21.8 nm and suitable zeta potential and polydispersity index values of -9.0 mV and 0.261, respectively. OTMS exhibited acceptable stability for 3 months. Transmission electron microscopy demonstrated the spherical morphology of micelles. OTMS was expected to cause no ocular irritation or blurring in vision as reflected by pH and refractive index measurements. The histopathological study revealed the safety of OTMS for ocular use. The fungal susceptibility testing using Candida albicans demonstrated the superiority of OTMS to VRC suspension, with greater and more durable growth inhibition. Therefore, ocular application of optimized VRC-loaded TMSs can be a promising treatment for ocular mycosis.

Fahmy, A. M., M. Hassan, D. A. El-Setouhy, S. A. Tayel, and A. M. Al-mahallawi, "Voriconazole Ternary Micellar Systems for the Treatment of Ocular Mycosis: Statistical Optimization and In Vivo Evaluation", Journal of Pharmaceutical Sciences , vol. 17, 2021.
Ahmed, H. H., O. M. Osman, H. M. Youssef, N. A. A. AlTaweel, and M. Saleh, "Von Willebrand Factor Propetide as a marker of disease activity in Systemic Sclerosis: Correlation with Clinical, Radiological and Biochemical parameters", The Egyptian Rheumatologist , vol. 25, issue 1, 2003.